A Phase 1b/2a, Open-Label, Non-Randomized Study of Birinapant in Combination with 5-azacitidine in Subjects with Myelodysplastic Syndrome who are Naive, Refractory or have Relapsed to 5-azacitidine Therapy

To determine the maximum tolerated dose (MTD), recommended Phase 2 and pharmacodynamics (PD) of birinapant (TL32711) when administered in combination with 5-azacitidine (5-AZA) in subjects with myelodysplastic syndrome (MDS) who are refractory or have relapsed to 5-aza therapy.

Study Number: 

PH 236213

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.